Cargando…
The COVID-19 mRNA BNT163b2 Vaccine Was Well Tolerated and Highly Immunogenic in Young Adults in Long Follow-Up after Haematopoietic Stem Cell Transplantation
Sixty five patients (18–31 years) who had received allogeneic haematopoietic stem cell transplantation (3–27 years from HSCT) were evaluated for the tolerance and immunogenicity of the COVID-19 mRNA BNT163b2 vaccine. Methods: Patients were vaccinated with two doses at 5 weeks interval. After each do...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539173/ https://www.ncbi.nlm.nih.gov/pubmed/34696317 http://dx.doi.org/10.3390/vaccines9101209 |
_version_ | 1784588682706026496 |
---|---|
author | Matkowska-Kocjan, Agnieszka Owoc-Lempach, Joanna Chruszcz, Joanna Kuźnik, Edwin Szenborn, Filip Jurczenko, Lidia Wójcik, Marta Banyś, Dorota Szenborn, Leszek Ussowicz, Marek |
author_facet | Matkowska-Kocjan, Agnieszka Owoc-Lempach, Joanna Chruszcz, Joanna Kuźnik, Edwin Szenborn, Filip Jurczenko, Lidia Wójcik, Marta Banyś, Dorota Szenborn, Leszek Ussowicz, Marek |
author_sort | Matkowska-Kocjan, Agnieszka |
collection | PubMed |
description | Sixty five patients (18–31 years) who had received allogeneic haematopoietic stem cell transplantation (3–27 years from HSCT) were evaluated for the tolerance and immunogenicity of the COVID-19 mRNA BNT163b2 vaccine. Methods: Patients were vaccinated with two doses at 5 weeks interval. After each dose, patients completed a survey concerning adverse events (AE) and anti-SARS-CoV-2 IgG antibodies were measured before the first vaccine dose (1stVD) and 14–21 days after the second dose (2ndVD). AE reported after 1stVD and 2ndVD, respectively were: fever 0%, 1.7%; fatigue 15.4%, 25.8%; headache 15.4%, 24.1%; chills 6.1%, 12.0%; muscle pain 15.4%, 24.1%; joint pain 3.0%, 6.9%; nausea 6.1%, 6.9%; pain at injection site 30.7%, 34.4%; swelling 3.0%, 10.3%; redness 0, 3.4%; pruritus 0, 5.2%; and axillary lymphadenopathy 3.0%, 1.7%. After 2ndVD, 96.5% patients were positive for anti-SARS-CoV-2 (GMC 3290.94 BAU/mL). No correlation presented between the antibody titer and symptoms of chronic Graft-versus-Host disease, total IgG, lymphocyte CD4+, or AE. Significantly higher titers were observed in COVID-19 convalescents, and inverse correlation (R(2) = −0.0925, p = 0.02) between the time from HSCT and titers after 2ndVD was present. Conclusions: The young adults after HSCT tolerate the COVID-19 mRNA vaccine well and show immunologic response. |
format | Online Article Text |
id | pubmed-8539173 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85391732021-10-24 The COVID-19 mRNA BNT163b2 Vaccine Was Well Tolerated and Highly Immunogenic in Young Adults in Long Follow-Up after Haematopoietic Stem Cell Transplantation Matkowska-Kocjan, Agnieszka Owoc-Lempach, Joanna Chruszcz, Joanna Kuźnik, Edwin Szenborn, Filip Jurczenko, Lidia Wójcik, Marta Banyś, Dorota Szenborn, Leszek Ussowicz, Marek Vaccines (Basel) Article Sixty five patients (18–31 years) who had received allogeneic haematopoietic stem cell transplantation (3–27 years from HSCT) were evaluated for the tolerance and immunogenicity of the COVID-19 mRNA BNT163b2 vaccine. Methods: Patients were vaccinated with two doses at 5 weeks interval. After each dose, patients completed a survey concerning adverse events (AE) and anti-SARS-CoV-2 IgG antibodies were measured before the first vaccine dose (1stVD) and 14–21 days after the second dose (2ndVD). AE reported after 1stVD and 2ndVD, respectively were: fever 0%, 1.7%; fatigue 15.4%, 25.8%; headache 15.4%, 24.1%; chills 6.1%, 12.0%; muscle pain 15.4%, 24.1%; joint pain 3.0%, 6.9%; nausea 6.1%, 6.9%; pain at injection site 30.7%, 34.4%; swelling 3.0%, 10.3%; redness 0, 3.4%; pruritus 0, 5.2%; and axillary lymphadenopathy 3.0%, 1.7%. After 2ndVD, 96.5% patients were positive for anti-SARS-CoV-2 (GMC 3290.94 BAU/mL). No correlation presented between the antibody titer and symptoms of chronic Graft-versus-Host disease, total IgG, lymphocyte CD4+, or AE. Significantly higher titers were observed in COVID-19 convalescents, and inverse correlation (R(2) = −0.0925, p = 0.02) between the time from HSCT and titers after 2ndVD was present. Conclusions: The young adults after HSCT tolerate the COVID-19 mRNA vaccine well and show immunologic response. MDPI 2021-10-19 /pmc/articles/PMC8539173/ /pubmed/34696317 http://dx.doi.org/10.3390/vaccines9101209 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Matkowska-Kocjan, Agnieszka Owoc-Lempach, Joanna Chruszcz, Joanna Kuźnik, Edwin Szenborn, Filip Jurczenko, Lidia Wójcik, Marta Banyś, Dorota Szenborn, Leszek Ussowicz, Marek The COVID-19 mRNA BNT163b2 Vaccine Was Well Tolerated and Highly Immunogenic in Young Adults in Long Follow-Up after Haematopoietic Stem Cell Transplantation |
title | The COVID-19 mRNA BNT163b2 Vaccine Was Well Tolerated and Highly Immunogenic in Young Adults in Long Follow-Up after Haematopoietic Stem Cell Transplantation |
title_full | The COVID-19 mRNA BNT163b2 Vaccine Was Well Tolerated and Highly Immunogenic in Young Adults in Long Follow-Up after Haematopoietic Stem Cell Transplantation |
title_fullStr | The COVID-19 mRNA BNT163b2 Vaccine Was Well Tolerated and Highly Immunogenic in Young Adults in Long Follow-Up after Haematopoietic Stem Cell Transplantation |
title_full_unstemmed | The COVID-19 mRNA BNT163b2 Vaccine Was Well Tolerated and Highly Immunogenic in Young Adults in Long Follow-Up after Haematopoietic Stem Cell Transplantation |
title_short | The COVID-19 mRNA BNT163b2 Vaccine Was Well Tolerated and Highly Immunogenic in Young Adults in Long Follow-Up after Haematopoietic Stem Cell Transplantation |
title_sort | covid-19 mrna bnt163b2 vaccine was well tolerated and highly immunogenic in young adults in long follow-up after haematopoietic stem cell transplantation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539173/ https://www.ncbi.nlm.nih.gov/pubmed/34696317 http://dx.doi.org/10.3390/vaccines9101209 |
work_keys_str_mv | AT matkowskakocjanagnieszka thecovid19mrnabnt163b2vaccinewaswelltoleratedandhighlyimmunogenicinyoungadultsinlongfollowupafterhaematopoieticstemcelltransplantation AT owoclempachjoanna thecovid19mrnabnt163b2vaccinewaswelltoleratedandhighlyimmunogenicinyoungadultsinlongfollowupafterhaematopoieticstemcelltransplantation AT chruszczjoanna thecovid19mrnabnt163b2vaccinewaswelltoleratedandhighlyimmunogenicinyoungadultsinlongfollowupafterhaematopoieticstemcelltransplantation AT kuznikedwin thecovid19mrnabnt163b2vaccinewaswelltoleratedandhighlyimmunogenicinyoungadultsinlongfollowupafterhaematopoieticstemcelltransplantation AT szenbornfilip thecovid19mrnabnt163b2vaccinewaswelltoleratedandhighlyimmunogenicinyoungadultsinlongfollowupafterhaematopoieticstemcelltransplantation AT jurczenkolidia thecovid19mrnabnt163b2vaccinewaswelltoleratedandhighlyimmunogenicinyoungadultsinlongfollowupafterhaematopoieticstemcelltransplantation AT wojcikmarta thecovid19mrnabnt163b2vaccinewaswelltoleratedandhighlyimmunogenicinyoungadultsinlongfollowupafterhaematopoieticstemcelltransplantation AT banysdorota thecovid19mrnabnt163b2vaccinewaswelltoleratedandhighlyimmunogenicinyoungadultsinlongfollowupafterhaematopoieticstemcelltransplantation AT szenbornleszek thecovid19mrnabnt163b2vaccinewaswelltoleratedandhighlyimmunogenicinyoungadultsinlongfollowupafterhaematopoieticstemcelltransplantation AT ussowiczmarek thecovid19mrnabnt163b2vaccinewaswelltoleratedandhighlyimmunogenicinyoungadultsinlongfollowupafterhaematopoieticstemcelltransplantation AT matkowskakocjanagnieszka covid19mrnabnt163b2vaccinewaswelltoleratedandhighlyimmunogenicinyoungadultsinlongfollowupafterhaematopoieticstemcelltransplantation AT owoclempachjoanna covid19mrnabnt163b2vaccinewaswelltoleratedandhighlyimmunogenicinyoungadultsinlongfollowupafterhaematopoieticstemcelltransplantation AT chruszczjoanna covid19mrnabnt163b2vaccinewaswelltoleratedandhighlyimmunogenicinyoungadultsinlongfollowupafterhaematopoieticstemcelltransplantation AT kuznikedwin covid19mrnabnt163b2vaccinewaswelltoleratedandhighlyimmunogenicinyoungadultsinlongfollowupafterhaematopoieticstemcelltransplantation AT szenbornfilip covid19mrnabnt163b2vaccinewaswelltoleratedandhighlyimmunogenicinyoungadultsinlongfollowupafterhaematopoieticstemcelltransplantation AT jurczenkolidia covid19mrnabnt163b2vaccinewaswelltoleratedandhighlyimmunogenicinyoungadultsinlongfollowupafterhaematopoieticstemcelltransplantation AT wojcikmarta covid19mrnabnt163b2vaccinewaswelltoleratedandhighlyimmunogenicinyoungadultsinlongfollowupafterhaematopoieticstemcelltransplantation AT banysdorota covid19mrnabnt163b2vaccinewaswelltoleratedandhighlyimmunogenicinyoungadultsinlongfollowupafterhaematopoieticstemcelltransplantation AT szenbornleszek covid19mrnabnt163b2vaccinewaswelltoleratedandhighlyimmunogenicinyoungadultsinlongfollowupafterhaematopoieticstemcelltransplantation AT ussowiczmarek covid19mrnabnt163b2vaccinewaswelltoleratedandhighlyimmunogenicinyoungadultsinlongfollowupafterhaematopoieticstemcelltransplantation |